Sobi commences tender offer for all outstanding shares of Dova Pharmaceuticals

Booking.com

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that it has commenced a tender offer through its indirect wholly owned subsidiary Dragonfly Acquisition Corp. (Dragonfly) to purchase all outstanding shares of Dova Pharmaceuticals, Inc. (Dova) (NASDAQ: DOVA), at a price of USD 27.50 per share in cash plus one non-tradeable Contingent Value Right (CVR). The CVR entitles Dova shareholders to an additional USD 1.50 per share if Dova achieves approval by the US Food and Drug Administration (FDA) of a “New Drug Application” or a “Supplemental New Drug Application” for any

Source: Sobi commences tender offer for all outstanding shares of Dova Pharmaceuticals

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.